ERBB2 and gastric cancer: HER2 is the first and most important target of gastric cancer, and the ToGA study confirmed that trastuzumab combined with chemotherapy can significantly prolong the overall survival of patients with HER2-positive advanced or metastatic gastric cancer (2).